MENU
+Compare
APLS
Stock ticker: NASDAQ
AS OF
Nov 26 closing price
Price
$21.59
Change
+$0.59 (+2.81%)
Capitalization
2.73B

APLS Apellis Pharmaceuticals Forecast, Technical & Fundamental Analysis

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade... Show more

APLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for APLS with price predictions
Nov 26, 2025

Aroon Indicator for APLS shows an upward move is likely

APLS's Aroon Indicator triggered a bullish signal on October 29, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 190 similar instances where the Aroon Indicator showed a similar pattern. In of the 190 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where APLS's RSI Oscillator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 21, 2025. You may want to consider a long position or call options on APLS as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for APLS just turned positive on November 24, 2025. Looking at past instances where APLS's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APLS advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

APLS moved below its 50-day moving average on October 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for APLS crossed bearishly below the 50-day moving average on November 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

APLS broke above its upper Bollinger Band on November 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. APLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.807) is normal, around the industry mean (27.349). P/E Ratio (59.972) is within average values for comparable stocks, (52.390). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.898). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (2.727) is also within normal values, averaging (331.774).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
APLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

APLS is expected to report earnings to fall 122.23% to -37 cents per share on March 04

Apellis Pharmaceuticals APLS Stock Earnings Reports
Q4'25
Est.
$-0.37
Q3'25
Beat
by $0.12
Q2'25
Beat
by $0.15
Q1'25
Missed
by $0.40
Q4'24
Beat
by $0.08
The last earnings report on October 30 showed earnings per share of $1.67, beating the estimate of $1.55. With 1.83M shares outstanding, the current market capitalization sits at 2.73B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics and drug delivery technologies to address chronic inflammatory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Medical Distributors
Address
100 Fifth Avenue
Phone
+1 617 977-5700
Employees
706
Web
https://www.apellis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGVBX27.920.25
+0.90%
American Funds Global Insight 529-C
JUSQX19.670.17
+0.87%
JPMorgan US Small Company R4
EMRYX17.260.12
+0.70%
VanEck Emerging Markets Y
BBTSX13.180.09
+0.69%
Bridge Builder Tax Managed Sm/Md Cp
APDNX19.090.09
+0.47%
Artisan Select Equity Advisor

APLS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with NEVPF. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+2.81%
NEVPF - APLS
41%
Loosely correlated
N/A
VNDA - APLS
40%
Loosely correlated
+6.20%
DNLI - APLS
38%
Loosely correlated
+1.49%
NUVL - APLS
38%
Loosely correlated
-0.73%
IMVT - APLS
38%
Loosely correlated
-1.04%
More